New insights into meningioma

Vranic, Andrej; Peyre, Matthieu; Kalamaridès, Michel

doi:10.1097/cco.0b013e3283571a06

Cited by 23 publications

(11 citation statements)

References 42 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgical resection with adjuvant radiation is often the first line of treatment and is recommended in cases in which disease is persistent or recurrent. 90 Meningiomas often manifest in the thoracic spine and are most common in female patients and in the fourth and fifth decade of life. 90,91 Unlike their intracranial counterparts, spinal meningiomas are unlikely to recur after surgical resection, with recurrence rates of 0–13% reported.…”

Section: Extramedullary Intradural Tumoursmentioning

confidence: 99%

“…90 Meningiomas often manifest in the thoracic spine and are most common in female patients and in the fourth and fifth decade of life. 90,91 Unlike their intracranial counterparts, spinal meningiomas are unlikely to recur after surgical resection, with recurrence rates of 0–13% reported. 24,88,92–94 …”

Section: Extramedullary Intradural Tumoursmentioning

confidence: 99%

“…90,95–99 In a microarray-based study of spinal and intracranial meningiomas, Sayagues and colleagues reported that homozygous chromosome 22 deletions were more likely to be associated with spinal than with intracranial meningiomas, and lesions isolated from the spine were likely to originate from a single-cell clone. 100 …”

Section: Extramedullary Intradural Tumoursmentioning

confidence: 99%

See 2 more Smart Citations

Spinal cord tumours: advances in genetics and their implications for treatment

et al. 2013

View full text Add to dashboard Cite

Tumours of the spinal cord, although rare, are associated with high morbidity. Surgical resection remains the primary treatment for patients with this disease, and offers the best chance for cure. Such surgical procedures, however, carry substantial risks such as worsening of neurological deficit, paralysis and death. New therapeutic avenues for spinal cord tumours are needed, but genetic studies of the molecular mechanisms governing tumourigenesis in the spinal cord are limited by the scarcity of high-quality human tumour samples. Many spinal cord tumours have intracranial counterparts that have been extensively studied, but emerging data show that the tumours are genetically and biologically distinct. The differences between brain and spine tumours make extrapolation of data from one to the other difficult. In this Review, we describe the demographics, genetics and current treatment approaches for the most commonly encountered spinal cord tumours—namely, ependymomas, astrocytomas, haemangioblastomas and meningiomas. We highlight advances in understanding of the biological basis of these lesions, and explain how the latest progress in genetics and beyond are being translated to improve patient care.

show abstract

Section: Extramedullary Intradural Tumoursmentioning

confidence: 99%

Section: Extramedullary Intradural Tumoursmentioning

confidence: 99%

Section: Extramedullary Intradural Tumoursmentioning

confidence: 99%

See 1 more Smart Citation

Spinal cord tumours: advances in genetics and their implications for treatment

et al. 2013

View full text Add to dashboard Cite

show abstract

“… 4 Over the last few years, an increasing attention has been paid to the molecular genetics of meningiomas. 5 Specific gene dysfunctions have been implicated in the pathogenesis of these tumors, including the inactivation of tumor suppressor genes or excessive expression of oncogenes. 6 However, a thorough understanding of the molecular basis of this tumor remains far from being well established.…”

Section: Introductionmentioning

confidence: 99%

<em>let-7d</em> suppresses proliferation and invasion and promotes apoptosis of meningioma by targeting AEG-1

Zhao

2017

OTT

View full text Add to dashboard Cite

Backgroundlet-7d has been indicated to act as a tumor suppressor in various cancers. However, the function and molecular mechanism of let-7d in meningioma progression have not been elucidated.Materials and methodsQuantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect the expression levels of let-7d and AEG-1 mRNA in meningioma tissues and cell lines. The protein level of AEG-1 was measured by Western blot analysis. MTT assay, Transwell invasion assay and flow cytometry analysis were carried out to determine the proliferation, invasion and apoptosis of IOMM-Lee and CH-157MN cells, respectively. Target gene of let-7d was verified by luciferase reporter analysis.Resultslet-7d expression was downregulated, and AEG-1 expression was upregulated in meningioma tumor tissues. let-7d overexpression suppressed proliferation and invasion and induced apoptosis in IOMM-Lee and CH-157MN cells. Moreover, AEG-1 was a direct target of let-7d. Restoration of AEG-1 expression reversed let-7d-mediated suppression of the proliferation and invasion and let-7d-induced apoptosis in IOMM-Lee and CH-157MN cells.Conclusionlet-7d repressed proliferation and invasion and promoted apoptosis of meningioma cells by targeting AEG-1. The present study provided a better understanding of the meningioma pathogenesis and a promising therapeutic target for meningioma patients.

show abstract

“…However, in case of further growth it can cause neurological symptoms related to brain and cranial nerve compression or irritation [ 4 ]. Thus, several recent studies have aimed to identify various genetic and molecular alterations of meningioma so as to identify new molecular markers and targeted therapies for early diagnosis and better clinical management of the disease [ 5 – 7 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of autoantibody signatures in meningioma patients using human proteome arrays

et al. 2017

View full text Add to dashboard Cite

Meningiomas are one of the most common tumors of the Central nervous system (CNS). This study aims to identify the autoantibody biomarkers in meningiomas using high-density human proteome arrays (~17,000 full-length recombinant human proteins). Screening of sera from 15 unaffected healthy individuals, 10 individuals with meningioma grade I and 5 with meningioma grade II was performed. This comprehensive proteomics based investigation revealed the dysregulation of 489 and 104 proteins in grades I and II of meningioma, respectively, along with the enrichment of several signalling pathways, which might play a crucial role in the manifestation of the disease. Autoantibody targets like IGHG4, CRYM, EFCAB2, STAT6, HDAC7A and CCNB1 were significantly dysregulated across both the grades. Further, we compared this to the tissue proteome and gene expression profile from GEO database. Previously reported upregulated proteins from meningioma tissue-based proteomics obtained from high-resolution mass spectrometry demonstrated an aggravated autoimmune response, emphasizing the clinical relevance of these targets. Some of these targets like SELENBP1 were tested for their presence in tumor tissue using immunoblotting. In the light of highly invasive diagnostic modalities employed to diagnose CNS tumors like meningioma, these autoantibody markers offer a minimally invasive diagnostic platform which could be pursued further for clinical translation.

show abstract

New insights into meningioma

Abstract: Surgical approach combined with radiotherapy in selected cases remains the most appropriate for meningioma patients. New therapies are under investigation and should modify treatment paradigms in the future.

Cited by 23 publications

References 42 publications

Spinal cord tumours: advances in genetics and their implications for treatment

Spinal cord tumours: advances in genetics and their implications for treatment

<em>let-7d</em> suppresses proliferation and invasion and promotes apoptosis of meningioma by targeting AEG-1

Evaluation of autoantibody signatures in meningioma patients using human proteome arrays

Contact Info

Product

Resources

About